CARB-X today announced the product themes for its latest funding round.
The global non-profit partnership, launched in 2016 to support early-stage antibacterial research and development (R&D) to address the rising threat of antimicrobial resistance, said its 2026 funding round will focus on four distinct product themes:
- Direct-acting therapeutics for infections caused by gram-negative bacteria
- Novel chemistry scaffolds with activity against validated bacterial targets
- Non-vaccine approaches for preventing neonatal sepsis
- Diagnostics for neonatal sepsis
In a news release, CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) Interim Chief of R&D Richard Alm, PhD, said the funding round is focused on aligning with the “areas of greatest unmet need and global public health impact.”
The organization highlighted recent estimates showing that a steady stream of new, potent antibiotics targeting gram-negative bacteria could avert up to 11.1 million cumulative deaths caused by antimicrobial resistance in the next 25 years, primarily in low- and middle-income countries (LMICs).
Neonatal sepsis, a theme of previous CARB-X funding rounds, causes an estimated 570,000 infant deaths a year worldwide, with LMICs bearing the highest burden.
“By focusing on priority Gram-negative bacteria, novel chemistry, and neonatal sepsis, we are directing innovation toward syndromes that drive the highest morbidity and mortality worldwide, particularly in low- and middle-income countries,” Alm said. “This disciplined, burden-driven approach ensures that CARB-X derisks innovation that is positioned for real-world impact.”
Since its inception, CARB-X has funded 122 early-stage projects designed to treat, prevent, and diagnose antibiotic-resistant infections. Fourteen of those projects are in late-stage clinical development, and three have reached the market.